0%
Print report
Variant interpretation report

PRPF8 c.6912C>T, p.Phe2304=

NM_006445.3:c.6912C>T NP_006436.3:p.(Phe2304=) Synonymous · exon 43 View identifiers
Classification
Uncertain significance

Variant description:

The PRPF8 NM_006445.3:c.6912C>T (NP_006436.3:p.(Phe2304=)) synonymous variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About PRPF8

PRPF8 encodes a core component of the spliceosome, the cellular machinery that removes introns from pre-mRNA during gene expression; it is essential for the catalytic second step of pre-mRNA splicing and helps assemble splicing complexes through its WD repeat domains. Mutations in PRPF8 are a known cause of autosomal dominant retinitis pigmentosa, an inherited form of progressive vision loss. In cancer, altered PRPF8 splicing disrupts the proofreading function of the spliceosome and is often found alongside TP53 loss-of-function mutations, implicating it in tumor development as a tumor suppressor.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 0
Pathogenic criteria applied · 1
PM2Moderate
PM2 · moderate

Met at Moderate: gnomAD v4.1 AF is 4.95644e-06, below the 0.0001 extremely-low-frequency PM2 cutoff.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: PM2 (moderate) is the only applied criterion, and it does not satisfy any generic ACMG/AMP pathogenic, likely pathogenic, benign, or likely benign combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
8 / 1,614,062 alleles

gnomAD v4.1: 8 / 1,614,062 alleles. Recorded AF 4.95644e-06. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.07219e-06; MAF= 0.00071%, 2/282798 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 8.01154e-05; MAF= 0.00801%, 2/24964 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI score
0.141 maximum delta

Recorded SpliceAI maximum delta score: 0.141. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied SpliceAI ↗
No screenshot for this evidence
ClinVar submissions
Not recorded

A ClinVar laboratory submission summary was not recorded.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: Unknown Oncogenic Effect.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 1 met · 8 not met · 10 not assessed · 9 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

No PS2, PM6, PP1, or BS4 evidence is established because the case contains no proband-level parental testing, family segregation, or affected-relative non-segregation data for PRPF8 NM_006445.3:c.6912C>T.

Published observations reviewed for PRPF8 concern different variants and cannot be transferred to this exact synonymous variant.

No VCEP covers PRPF8; generic ACMG/AMP 2015 rules govern.

The exact variant is synonymous, absent from ClinVar, and not reported in the reviewed PRPF8 cohort papers; reported same-codon substitutions are different variants and were not used as evidence for this variant.

Generic ACMG/AMP 2015 rules govern because no VCEP covers PRPF8.

The variant is synonymous, so PP3 and BP4 use the SpliceAI path only; REVEL and BayesDel are not used.

SpliceAI max delta 0.141 is below the PP3 threshold of 0.2 and above the BP4/no-impact cutoff of 0.1; no computational criterion among PP3, BP4, and BP7 is met.

Met · 1

PM2 ModerateACMGMet at Moderate: gnomAD v4.1 AF is 4.95644e-06, below the 0.0001 extremely-low-frequency PM2 cutoff. Details ▾Hide ▴
Reasoning

PM2 is met at Moderate strength under the governing generic ACMG/AMP 2015 rules. The generic PM2 cutoff supplied for extremely low frequency is <=0.0001. gnomAD v4.1 shows the variant at AF 4.95644e-06 (8/1,614,062 alleles), with filtering grpmax FAF 4.43e-06 and no homozygotes; this is below the cutoff. No VCEP-specific non-cancer or exome-only population source governs this gene, so the default all-comers gnomAD v4.1 entry is used.

Rule
PM2 (moderate): <= 0.0001 — ACMG/AMP 2015 PM2 (Richards et al. 2015); 0.01% is the generic cutoff for 'extremely low frequency' (PMID:25741868) ... Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 all-comers: 8/1,614,062 alleles, AF=4.95644e-06, grpmax FAF=4.43e-06, and homozygotes=0; no governing VCEP or non-cancer/exome-only population specification was identified.
Sources

Not met · 8 · evaluated, threshold not reached

PS4 ACMG_2015Not met: reviewed cohorts did not report PRPF8 c.6912C>T, so no affected-versus-control counts, odds ratio, or confidence interval support PS4. Details ▾Hide ▴
Reasoning

Generic ACMG/AMP PS4 requires a significantly increased prevalence in affected individuals compared with controls; the 2015 Note 1 strong threshold is OR >5.0 with a confidence interval that excludes 1.0. The exact synonymous variant NM_006445.3:c.6912C>T (p.=) was not reported in the reviewed PRPF8 retinitis-pigmentosa cohort papers. The papers reported different PRPF8 variants, including c.6912C>G, but supplied no affected-versus-control counts for c.6912C>T, so no case-control OR or 95% CI can be calculated and PS4 strong is not met.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • PMID:11468273: the paper reports PRPF8 c.6953C>G (F2304L) in two affected siblings, not c.6912C>T; no exact-variant control comparison is provided.
  • PMID:16799052: the paper reports c.6912C>G (Phe2304Leu) in one family, not c.6912C>T; no exact-variant case-control data are provided.
  • PMID:23950152: Table 3 reports c.6912C>G (Phe2304Leu) once among 170 probands, not c.6912C>T; no exact-variant controls are reported.
  • PMID:28076437 and PMID:33576794: the reviewed cohorts do not report the exact c.6912C>T variant.
  • gnomAD v4.1 reports the exact variant at 8/1,614,062 alleles (AF 4.95644e-06), but no affected-case prevalence is available; therefore an OR and 95% CI cannot be computed from matched case-control counts.
Still missing
  • No published affected-case and control counts for the exact c.6912C>T variant were identified.
Sources
PP3 ACMGNot met: SpliceAI max delta 0.141 is below the >=0.2 PP3 supporting threshold. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_006445.3:c.6912C>T; NP_006436.3:p.(Phe2304=)), so the applicable generic computational path is SpliceAI only; REVEL is not applicable. SpliceAI max delta is 0.141, which is below the supplied PP3 supporting threshold of >= 0.2. Therefore PP3 is not met at the ACMG/AMP 2015 supporting strength.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... Intronic, synonymous, or splice-region variant -> SpliceAI only. There is no REVEL score to fall back to.
Evidence considered
  • Case normalization identifies NM_006445.3:c.6912C>T as synonymous, NP_006436.3:p.(Phe2304=), in exon 43.
  • SpliceAI source data reports max delta score 0.141 (DS_AG 0.141; DS_AL 0.002; DS_DG 0.0; DS_DL 0.005).
  • The supplied generic PP3 threshold is SpliceAI max delta >= 0.2 at supporting strength, based on Jaganathan et al. 2019 (PMID:30661751).
Sources
PP5 ACMGNot met: the exact variant is absent from ClinVar, with zero submissions and zero expert-panel pathogenic or likely-pathogenic classifications. Details ▾Hide ▴
Reasoning

PP5 requires a reputable recent pathogenic report when the evidence is unavailable for independent evaluation, and the generic rule here limits PP5 to an exact-variant ClinVar expert-panel classification of Pathogenic or Likely pathogenic. The exact variant is absent from the ClinVar audit: there are zero submissions and zero expert-panel submissions. Therefore PP5 is not met.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation. ... Generic rules for PP5/BP6: apply them only for an exact-variant ClinVar expert-panel classification: Pathogenic/Likely pathogenic supports PP5; Benign/Likely benign supports BP6.
Evidence considered
  • ClinVar submission audit: exact match false; submissions total 0; expert-panel submissions 0; the exact variant is absent from ClinVar.
BA1 ACMG_2015Not met: gnomAD v4.1 grpmax FAF is 4.43e-06, far below the 0.05 BA1 threshold. Details ▾Hide ▴
Reasoning

BA1 is not met. The governing generic rule requires an allele frequency above 5% in ESP, 1000 Genomes, or ExAC. The available default all-comers gnomAD v4.1 data show 8/1,614,062 alleles (AF 4.95644e-06), with grpmax FAF 4.43e-06; this is far below 0.05. No VCEP-specific population source applies, and no small-population popmax point estimate can override the grpmax FAF requirement.

Rule
Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 all-comers: 8/1,614,062 alleles, total AF=4.95644e-06, homozygotes=0, grpmax FAF=4.43e-06; the highest observed African/African American point estimate was 2/74,920 alleles (AF=2.66951e-05).
Sources
BS1 ACMGNot met: gnomAD v4.1 grpmax FAF is 4.43e-06, below the generic 0.01 BS1 threshold. Details ▾Hide ▴
Reasoning

BS1 is not met. BS1 requires an allele frequency greater than expected for the disorder; the supplied generic default threshold is 0.01. The filtering metric required here, gnomAD v4.1 grpmax FAF, is 4.43e-06, and the total AF is 4.95644e-06, both far below 0.01. The observed frequency therefore does not support BS1, without needing a disease-specific maximum-credible-frequency calculation.

Rule
Generic rules for BS1: the criterion is 'allele frequency is greater than expected for the disorder'; the 1% figure is only a default. ... BS1 (strong): >= 0.01 — Generic SVI default; per-gene derivation preferred (Whiffin et al. 2017) (PMID:28518168)
Evidence considered
  • gnomAD v4.1 filtering frequency: grpmax FAF=4.43e-06; total AF=4.95644e-06 from 8/1,614,062 alleles, with no homozygotes.
Sources
BP4 ACMGNot met: SpliceAI max delta 0.141 exceeds the <=0.1 BP4 no-impact threshold. Details ▾Hide ▴
Reasoning

The variant is synonymous, so the applicable generic computational path is SpliceAI only; REVEL is not applicable. SpliceAI max delta is 0.141, which exceeds the supplied BP4 supporting threshold of <= 0.1. Therefore BP4 is not met at the ACMG/AMP 2015 supporting strength; the SpliceAI result cannot be supplemented with another predictor path.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc) ... Intronic, synonymous, or splice-region variant -> SpliceAI only. There is no REVEL score to fall back to.
Evidence considered
  • Case normalization identifies NM_006445.3:c.6912C>T as synonymous, NP_006436.3:p.(Phe2304=), in exon 43.
  • SpliceAI source data reports max delta score 0.141 (DS_AG 0.141; DS_AL 0.002; DS_DG 0.0; DS_DL 0.005).
  • The supplied generic BP4 threshold is SpliceAI max delta <= 0.1 at supporting strength, based on Jaganathan et al. 2019 (PMID:30661751).
Sources
BP6 ACMGNot met: the exact variant is absent from ClinVar, with zero submissions and zero expert-panel benign or likely-benign classifications. Details ▾Hide ▴
Reasoning

BP6 requires a reputable recent benign report when the evidence is unavailable for independent evaluation, and the generic rule here limits BP6 to an exact-variant ClinVar expert-panel classification of Benign or Likely benign. The exact variant is absent from the ClinVar audit: there are zero submissions and zero expert-panel submissions. Therefore BP6 is not met.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation. ... Generic rules for PP5/BP6: apply them only for an exact-variant ClinVar expert-panel classification: Pathogenic/Likely pathogenic supports PP5; Benign/Likely benign supports BP6.
Evidence considered
  • ClinVar submission audit: exact match false; submissions total 0; expert-panel submissions 0; the exact variant is absent from ClinVar.
BP7 ACMG_2015Not met: SpliceAI max delta 0.141 is above the supplied <=0.1 no-impact cutoff. Details ▾Hide ▴
Reasoning

BP7 is applicable because the variant is synonymous. However, the available SpliceAI max delta is 0.141, above the supplied <= 0.1 no-impact cutoff used for the generic splice-prediction path, so the required prediction of no splice impact is not established. The available evidence also does not establish that the nucleotide is not highly conserved. BP7 is therefore not met at supporting strength.

Rule
BP7: A synonymous variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved.
Evidence considered
  • Case normalization identifies NM_006445.3:c.6912C>T as synonymous, NP_006436.3:p.(Phe2304=), in exon 43.
  • SpliceAI source data reports max delta score 0.141 (DS_AG 0.141; DS_AL 0.002; DS_DG 0.0; DS_DL 0.005), which does not meet the supplied no-impact cutoff of <= 0.1.
  • No reliable case-specific evidence establishes that the substituted nucleotide is not highly conserved.
Sources

Not assessed · 10 · no assessment recorded

PS2 ACMG_2015Not assessed: no proband-level de novo observation or confirmed maternity and paternity is documented for PRPF8 c.6912C>T. Details ▾Hide ▴
Reasoning

No case-level evidence establishes that PRPF8 NM_006445.3:c.6912C>T occurred de novo in a patient with the disease. The available evidence does not document a proband, disease phenotype, family history, or confirmed maternity and paternity for this exact variant; therefore the PS2 definition cannot be evaluated.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • The case evidence identifies the variant as PRPF8 NM_006445.3:c.6912C>T, predicted synonymous p.(Phe2304=), but provides no proband or parental-testing record for this exact variant.
  • The literature extracts reviewed for PRPF8 retinal-dystrophy studies report other PRPF8 variants, not c.6912C>T, and therefore do not establish de novo status for this variant.
Still missing
  • A documented affected proband carrying PRPF8 NM_006445.3:c.6912C>T
  • Disease phenotype and family-history information for that proband
  • Variant testing in both biological parents with confirmed maternity and paternity
Sources
PS3 ACMG_2015Not assessed: no functional assay tested the exact c.6912C>T synonymous variant, while available assays studied different PRPF8 substitutions. Details ▾Hide ▴
Reasoning

No well-established in vitro or in vivo functional study of the exact synonymous variant NM_006445.3:c.6912C>T (NP_006436.3:p.(Phe2304=)) was identified. PMID:17934474 reports yeast, binding, spliceosome-assembly, and splicing assays for other PRPF8 retinitis-pigmentosa variants; PMID:17317632 reports a yeast two-hybrid assay for the different missense substitution F2304L; and PMID:17473007 reports structural/biochemical studies of other C-terminal mutants. These results establish biological relevance of the PRPF8 C-terminal region but cannot be transferred to the queried synonymous substitution, so PS3 cannot be assessed at a 2015 strong strength.

Rule
PS3: Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product. ... Note: Functional studies that have been validated and shown to be reproducible and robust in a clinical diagnostic laboratory setting are considered the most well-established.
Evidence considered
  • PMID:17934474: Functional studies used yeast growth, in vitro binding and splicing assays, immunoprecipitation, glycerol-gradient fractionation, northern analysis, RT-PCR, microarray analysis, and microscopy for other PRPF8 retinitis-pigmentosa-associated mutations; the exact c.6912C>T variant was not mentioned.
  • PMID:17317632: A targeted yeast two-hybrid assay found that the different missense substitution F2304/2382L affected interaction with human Brr2, not the queried synonymous substitution.
  • PMID:17473007: Structural and biochemical studies addressed other C-terminal Prp8 mutants and did not experiment on c.6912C>T or p.F2304=.
  • No assay controls, reproducibility data, or clinical diagnostic-laboratory validation specific to c.6912C>T were available for PS3 calibration.
Still missing
  • A validated, reproducible functional assay directly testing PRPF8 c.6912C>T or its RNA-splicing consequence is unavailable.
Sources
PM6 ACMG_2015Not assessed: no affected proband with PRPF8 c.6912C>T and assumed de novo status is documented, regardless of parental confirmation. Details ▾Hide ▴
Reasoning

No case-level evidence establishes an assumed de novo occurrence of PRPF8 NM_006445.3:c.6912C>T. The available evidence does not document an affected proband carrying this exact variant or the parental-testing circumstances needed to distinguish PM6 from PS2; therefore PM6 cannot be evaluated.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • The case evidence identifies PRPF8 NM_006445.3:c.6912C>T but contains no affected-proband report or parental-testing result for this exact variant.
  • The reviewed PRPF8 publications concern different variants and do not provide assumed de novo evidence for c.6912C>T.
Still missing
  • A documented affected proband carrying PRPF8 NM_006445.3:c.6912C>T
  • Evidence that the variant was considered de novo
  • Parental testing details, including whether maternity or paternity was confirmed
Sources
PP1 ACMG_2015Not assessed: zero affected relatives or informative meioses are documented for segregation of PRPF8 c.6912C>T. Details ▾Hide ▴
Reasoning

No affected family members carrying PRPF8 NM_006445.3:c.6912C>T are documented, and no meioses or segregation results are available for this exact variant. Reports of segregation for other PRPF8 substitutions cannot be transferred to the queried synonymous variant, so PP1 cannot be evaluated.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease. ... May be used as stronger evidence with increasing segregation data.
Evidence considered
  • The case evidence contains no family pedigree or segregation data for PRPF8 NM_006445.3:c.6912C>T.
  • PMID:11468273 reports two affected siblings with a different PRPF8 F2304L variant, and PMID:23950152 reports PRPF8 c.6912C>G; neither is segregation evidence for c.6912C>T.
Still missing
  • Affected relatives carrying the exact PRPF8 NM_006445.3:c.6912C>T variant
  • Unaffected relatives tested for the exact variant
  • Informative meioses and phenotype status for each tested family member
Sources
PP4 ACMG_2015Not assessed: the supplied evidence lacks patient phenotype and family-history details needed to judge whether the presentation is highly specific for a single etiology. Details ▾Hide ▴
Reasoning

PP4 requires a patient's phenotype or family history that is highly specific for a disease with a single genetic etiology. The supplied case evidence identifies PRPF8 and retinitis-pigmentosa literature but does not provide the patient's phenotype or family history in a form that permits assessment of specificity; PP4 is therefore not assessed.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Still missing
  • Patient phenotype and family-history details are missing.
BS2 ACMG_2015Not assessed: gnomAD shows two heterozygous alleles but does not establish healthy-adult status or early full penetrance. Details ▾Hide ▴
Reasoning

BS2 is not assessed. The rule requires observation in a healthy adult individual for a recessive homozygous, dominant heterozygous, or X-linked hemizygous disorder, with full penetrance expected at an early age. gnomAD reports two heterozygous alleles in African/African American individuals and no homozygotes, but it does not establish that any carrier was a clinically healthy adult, confirm the relevant phenotype status, or establish early full penetrance for the PRPF8-associated disorder. Population allele counts alone are insufficient for BS2.

Rule
Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v4.1 reports 2 variant alleles among 74,920 African/African American alleles, no homozygotes, and does not provide individual-level phenotype or healthy-adult status.
Still missing
  • A source documenting a clinically healthy adult heterozygote with verified age and phenotype status is needed.
  • The disorder's age-dependent penetrance must be established before applying BS2.
Sources
BS3 ACMG_2015Not assessed: no well-established assay demonstrated normal protein function or splicing for the exact c.6912C>T synonymous variant. Details ▾Hide ▴
Reasoning

No well-established in vitro or in vivo functional study of the exact synonymous variant NM_006445.3:c.6912C>T (NP_006436.3:p.(Phe2304=)) demonstrated no damaging effect on protein function or splicing. The available functional publications studied other PRPF8 variants, including F2304L and other C-terminal substitutions, and therefore neither establish a benign result nor provide variant-specific assay controls or reproducibility for c.6912C>T. BS3 cannot be assessed at a 2015 strong strength.

Rule
BS3: Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • PMID:17934474: Functional assays of other PRPF8 mutations reported impaired U5 snRNP maturation and splicing-related effects; they did not test c.6912C>T and cannot establish a benign effect for it.
  • PMID:17317632: The assay examined the different F2304L missense substitution in a yeast two-hybrid system and provides no normal-function result for the synonymous c.6912C>T variant.
  • PMID:17473007: Structural/biochemical work on other C-terminal mutants did not test c.6912C>T or p.F2304=.
  • No assay controls, reproducibility data, or clinical diagnostic-laboratory validation specific to c.6912C>T were available for BS3 calibration.
Still missing
  • A validated, reproducible functional assay directly showing no damaging effect of PRPF8 c.6912C>T on protein function or splicing is unavailable.
Sources
BS4 ACMG_2015Not assessed: no affected relative tested negative for PRPF8 c.6912C>T is documented. Details ▾Hide ▴
Reasoning

No affected family members have been documented as lacking PRPF8 NM_006445.3:c.6912C>T, and no family testing or phenotype-linked non-segregation data are available for this exact variant. Consequently, lack of segregation cannot be assessed; no BS4 evidence is established.

Rule
Lack of segregation in affected members of a family. ... Caveat: The presence of phenocopies for common phenotypes (i.e. cancer, epilepsy) can mimic lack of segregation among affected individuals.
Evidence considered
  • The case evidence provides no affected-relative testing results or family-level phenotype data for PRPF8 NM_006445.3:c.6912C>T.
  • The reviewed publications describe other PRPF8 variants and do not demonstrate non-segregation of the queried synonymous variant.
Still missing
  • A family with affected members evaluated for PRPF8 NM_006445.3:c.6912C>T
  • Negative variant-testing results in affected relatives
  • Phenotype and family-structure information sufficient to interpret non-segregation
Sources
BP2 ACMG_2015Not assessed: no parental/offspring phase data or pathogenic partner establishes the queried variant in trans or cis. Details ▾Hide ▴
Reasoning

The PRPF8 literature supports an autosomal-dominant retinitis pigmentosa disease context, so the dominant-disorder branch of BP2 is applicable. However, no case-level evidence establishes NM_006445.3:c.6912C>T in trans with a pathogenic variant or in cis with a pathogenic variant, and no parental or offspring testing is reported for this queried synonymous variant. The available literature concerns other PRPF8 variants, including c.6912C>G, and cannot substitute for phase evidence for c.6912C>T; BP2 therefore remains not assessed.

Rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • Mutations in the pre-mRNA splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa, Results/Table 1: the disease cohort and reported PRPF8 observations are autosomal dominant, but the reported variant is different from c.6912C>T.
  • Prevalence of mutations in eyeGENE probands with a diagnosis of autosomal dominant retinitis pigmentosa, Results/Table 3: PRPF8 c.6912C>G (p.Phe2304Leu) was reported once; this is not the queried c.6912C>T and provides no phase data for it.
Still missing
  • Case-level identification of a pathogenic variant in the same individual.
  • Parental or offspring testing establishing whether the queried variant is in trans or cis with that pathogenic variant.
  • Confirmation that the pathogenic partner and phase observation apply specifically to NM_006445.3:c.6912C>T.
Sources
BP5 ACMG_2015Not assessed: no case carrying the exact variant with an independently established alternate molecular basis for disease is documented. Details ▾Hide ▴
Reasoning

BP5 requires the variant to be found in a case with an alternate molecular basis for disease. No exact-variant case report with an alternate molecular diagnosis is documented in the supplied evidence, and the available literature concerns other PRPF8 variants; the required case-level information is insufficient to assess BP5.

Rule
Variant found in a case with an alternate molecular basis for disease.
Still missing
  • A case-level alternate molecular diagnosis for an individual carrying c.6912C>T is not available.
Not applicable · 9· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_006445.3:c.6912C>T in PRPF8 is a synonymous (silent) substitution predicted to produce NP_006436.3:p.(Phe2304=). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for PRPF8, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PS1 N/ANot applicable: PS1 requires a missense variant, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PS1 (Richards et al. 2015, PMID:25741868) requires the same amino acid change as a previously established pathogenic variant, evaluated regardless of the underlying nucleotide change. NM_006445.3:c.6912C>T in PRPF8 is a synonymous (silent) substitution predicted to produce NP_006436.3:p.(Phe2304=). As a result, no altered amino acid exists at this position to compare against any previously established pathogenic missense variant, so PS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PS1 for PRPF8, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PM1 N/ANot applicable: PM1 requires a missense variant, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PM1 (Richards et al. 2015, PMID:25741868) applies to a missense variant located in a mutational hot spot and/or a critical, well-established functional domain without benign variation. NM_006445.3:c.6912C>T in PRPF8 is a synonymous (silent) substitution predicted to produce NP_006436.3:p.(Phe2304=). As a result, no altered residue exists to evaluate for mutational hot-spot or critical-domain membership, so PM1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM1 for PRPF8, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PM3 N/ANot applicable: PRPF8 retinitis pigmentosa is described as autosomal dominant, whereas PM3 is restricted to recessive disorders. Details ▾Hide ▴
Reasoning

PM3 is restricted to recessive disorders and requires the assessed variant to be detected in trans with a pathogenic variant, with phase established by parental or offspring testing. The available PRPF8 disease literature describes autosomal-dominant retinitis pigmentosa, including affected heterozygous siblings, rather than a recessive PRPF8 disorder. Therefore PM3 is not applicable to this disorder context; no PM3 evidence is assigned to the synonymous NM_006445.3:c.6912C>T variant.

Rule
For recessive disorders, detected in trans with a pathogenic variant ... This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • Mutations in the pre-mRNA splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa, Results/Table 1: affected siblings were heterozygous for a PRPF8 variant; the study evaluates autosomal-dominant retinitis pigmentosa.
  • Prevalence of mutations in eyeGENE probands with a diagnosis of autosomal dominant retinitis pigmentosa, cohort findings: PRPF8 mutations were assessed in 170 autosomal-dominant retinitis pigmentosa probands; the reported same-position change was c.6912C>G, not the queried c.6912C>T variant.
Sources
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_006445.3:c.6912C>T in PRPF8 is a synonymous (silent) substitution predicted to produce NP_006436.3:p.(Phe2304=). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for PRPF8, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM5 N/ANot applicable: PM5 requires a missense variant, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PM5 (Richards et al. 2015, PMID:25741868) requires a novel missense change at an amino acid residue where a different missense change has previously been determined to be pathogenic. NM_006445.3:c.6912C>T in PRPF8 is a synonymous (silent) substitution predicted to produce NP_006436.3:p.(Phe2304=). As a result, no missense change exists at this residue to compare against a different pathogenic missense change at the same position, so PM5's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM5 for PRPF8, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PP2 N/ANot applicable: PP2 requires a missense variant, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PP2 (Richards et al. 2015, PMID:25741868) applies to a missense variant in a gene with a low rate of benign missense variation, where missense variants are a common mechanism of disease. NM_006445.3:c.6912C>T in PRPF8 is a synonymous (silent) substitution predicted to produce NP_006436.3:p.(Phe2304=). As a result, the gene's missense-constraint properties are irrelevant because no missense change is present to evaluate, so PP2's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PP2 for PRPF8, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
BP1 N/ANot applicable: BP1 requires a missense variant, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

BP1 (Richards et al. 2015, PMID:25741868) applies to a missense variant in a gene for which primarily truncating variants are known to cause disease. NM_006445.3:c.6912C>T in PRPF8 is a synonymous (silent) substitution predicted to produce NP_006436.3:p.(Phe2304=). As a result, the gene's truncating-variant mechanism is irrelevant because no missense change is present to evaluate, so BP1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP1 for PRPF8, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_006445.3:c.6912C>T in PRPF8 is a synonymous (silent) substitution predicted to produce NP_006436.3:p.(Phe2304=). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for PRPF8, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules

Identifiers

Gene
PRPF8
Transcript
NM_006445.3
Coding (HGVS c.)
NM_006445.3:c.6912C>T
Protein (HGVS p.)
NP_006436.3:p.(Phe2304=)
GRCh38
chr17:1650898 G>A
GRCh37
chr17:1554192 G>A
Location and type
Exon 43 · synonymous

Gene diagram

Every interpreted variant in PRPF8, mapped onto the exon structure of NM_006445.3. Select a row to find it on the plot.

PRPF8NM_006445.3
Fetching transcript structure from UCSC…
gnomAD v4.1 8 / 1,614,062 alleles AF 4.96e-06 · 0 homozygotes · FAF 4.43e-06
gnomAD v2.1 2 / 282,798 alleles AF 7.07e-06 · 0 homozygotes
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 5e-06 · 8 / 1,614,062 alleles · 0 hom · FAF 4.4e-06
African/African American2 / 74,920 2.7e-05
European (non-Finnish)6 / 1,180,028 5.1e-06
0 alternate alleles recorded in 8 other groups: Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish.

gnomAD v2.1

AF 7.1e-06 · 2 / 282,798 alleles · 0 hom
African/African American2 / 24,964 8e-05
0 alternate alleles recorded in 7 other groups: Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), European (non-Finnish), Remaining individuals, South Asian.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 4.95644e-06; MAF= 0.00050%, 8/1614062 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 2.66951e-05; MAF= 0.00267%, 2/74920 alleles, homozygotes = 0); grpmax FAF= 4.43e-06.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.07219e-06; MAF= 0.00071%, 2/282798 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 8.01154e-05; MAF= 0.00801%, 2/24964 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +58 bp
0.002
SpliceAI acceptor gainat -52 bp
0.141
SpliceAI donor lossat -9 bp
0.005
SpliceAI donor gainat +59 bp
0.000
Pangolin splice lossmagnitude shown
-0.069
Pangolin splice gain
0.059

Other predictors

REVEL
Not available
BayesDel
Not available

How the predictions were used

PP3 ACMGNot met: SpliceAI max delta 0.141 is below the >=0.2 PP3 supporting threshold. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_006445.3:c.6912C>T; NP_006436.3:p.(Phe2304=)), so the applicable generic computational path is SpliceAI only; REVEL is not applicable. SpliceAI max delta is 0.141, which is below the supplied PP3 supporting threshold of >= 0.2. Therefore PP3 is not met at the ACMG/AMP 2015 supporting strength.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... Intronic, synonymous, or splice-region variant -> SpliceAI only. There is no REVEL score to fall back to.
Evidence considered
  • Case normalization identifies NM_006445.3:c.6912C>T as synonymous, NP_006436.3:p.(Phe2304=), in exon 43.
  • SpliceAI source data reports max delta score 0.141 (DS_AG 0.141; DS_AL 0.002; DS_DG 0.0; DS_DL 0.005).
  • The supplied generic PP3 threshold is SpliceAI max delta >= 0.2 at supporting strength, based on Jaganathan et al. 2019 (PMID:30661751).
Sources
BP4 ACMGNot met: SpliceAI max delta 0.141 exceeds the <=0.1 BP4 no-impact threshold. Details ▾Hide ▴
Reasoning

The variant is synonymous, so the applicable generic computational path is SpliceAI only; REVEL is not applicable. SpliceAI max delta is 0.141, which exceeds the supplied BP4 supporting threshold of <= 0.1. Therefore BP4 is not met at the ACMG/AMP 2015 supporting strength; the SpliceAI result cannot be supplemented with another predictor path.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc) ... Intronic, synonymous, or splice-region variant -> SpliceAI only. There is no REVEL score to fall back to.
Evidence considered
  • Case normalization identifies NM_006445.3:c.6912C>T as synonymous, NP_006436.3:p.(Phe2304=), in exon 43.
  • SpliceAI source data reports max delta score 0.141 (DS_AG 0.141; DS_AL 0.002; DS_DG 0.0; DS_DL 0.005).
  • The supplied generic BP4 threshold is SpliceAI max delta <= 0.1 at supporting strength, based on Jaganathan et al. 2019 (PMID:30661751).
Sources
BP7 ACMG_2015Not met: SpliceAI max delta 0.141 is above the supplied <=0.1 no-impact cutoff. Details ▾Hide ▴
Reasoning

BP7 is applicable because the variant is synonymous. However, the available SpliceAI max delta is 0.141, above the supplied <= 0.1 no-impact cutoff used for the generic splice-prediction path, so the required prediction of no splice impact is not established. The available evidence also does not establish that the nucleotide is not highly conserved. BP7 is therefore not met at supporting strength.

Rule
BP7: A synonymous variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved.
Evidence considered
  • Case normalization identifies NM_006445.3:c.6912C>T as synonymous, NP_006436.3:p.(Phe2304=), in exon 43.
  • SpliceAI source data reports max delta score 0.141 (DS_AG 0.141; DS_AL 0.002; DS_DG 0.0; DS_DL 0.005), which does not meet the supplied no-impact cutoff of <= 0.1.
  • No reliable case-specific evidence establishes that the substituted nucleotide is not highly conserved.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.14).

0 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata.

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 4.95644e-06; MAF= 0.00050%, 8/1614062 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 2.66951e-05; MAF= 0.00267%, 2/74920 alleles, homozygotes = 0); grpmax FAF= 4.43e-06.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.07219e-06; MAF= 0.00071%, 2/282798 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 8.01154e-05; MAF= 0.00801%, 2/24964 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant is absent from ClinVar.

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.14).

Functional

OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: Unknown Oncogenic Effect.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.